Avai Bio (AVAI) Common Equity (2018 - 2025)
Avai Bio's Common Equity history spans 7 years, with the latest figure at -$1.5 million for Q1 2024.
- On a quarterly basis, Common Equity fell 131.59% to -$1.5 million in Q1 2024 year-over-year; TTM through Mar 2024 was -$1.5 million, a 131.59% decrease, with the full-year FY2024 number at -$1.5 million, down 131.59% from a year prior.
- Common Equity hit -$1.5 million in Q1 2024 for Avai Bio, down from -$1.4 million in the prior quarter.
- Over the last five years, Common Equity for AVAI hit a ceiling of $73227.0 in Q3 2020 and a floor of -$1.5 million in Q1 2024.
- Historically, Common Equity has averaged -$564520.1 across 5 years, with a median of -$429921.0 in 2022.
- Biggest five-year swings in Common Equity: surged 159.78% in 2020 and later crashed 768.79% in 2021.
- Tracing AVAI's Common Equity over 5 years: stood at -$334124.0 in 2020, then grew by 2.01% to -$327413.0 in 2021, then tumbled by 64.77% to -$539482.0 in 2022, then crashed by 159.67% to -$1.4 million in 2023, then fell by 4.69% to -$1.5 million in 2024.
- Business Quant data shows Common Equity for AVAI at -$1.5 million in Q1 2024, -$1.4 million in Q4 2023, and -$991302.0 in Q3 2023.